Short-term Use Of Intermittent PTH To Accelerate Healing Of Stress Fractures And During Bisphosphonate Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$633,331.00
Summary
Osteoporosis treatments prevent fractures by hindering cells that erode the skeleton. Normally, those cells also repair injuries like stress fractures. Some patients, treated for long periods, can suffer fractures because the treatment slows bone healing. We have an innovative model to test alternative treatments to accelerate stress fracture healing, while osteoporosis treatment continues. This could prevent unusual stress fractures, in patients who still need the bone-sparing effectiveness of ....Osteoporosis treatments prevent fractures by hindering cells that erode the skeleton. Normally, those cells also repair injuries like stress fractures. Some patients, treated for long periods, can suffer fractures because the treatment slows bone healing. We have an innovative model to test alternative treatments to accelerate stress fracture healing, while osteoporosis treatment continues. This could prevent unusual stress fractures, in patients who still need the bone-sparing effectiveness of osteoporosis treatment.Read moreRead less
The Role Of Adjuvant Zoledronic Acid In Locally Advanced Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$384,132.00
Summary
This project seeks to confirm the highly encouraging early findings from the RADAR prostate cancer trial so that the new treatments tested can be brought in to clinical practice. The trial involved 1071 men at 23 cancer treatment centres in ANZ who had developed extensive cancerous masses in their prostates but without evidence of spread. All received their trial treatments between 2003 and 2007. This project involves the collection and analysis of follow up information up until September 2017.
A Randomised Trial Of Zoledronic Acid For Osteoarthritis Of The Knee
Funder
National Health and Medical Research Council
Funding Amount
$989,238.00
Summary
Osteoarthritis (OA) is the most common form of arthritis and is increasing markedly due to an ageing population. Despite its large disease burden, there are currently no approved disease-modifying drugs available which modify structural progression of OA. The aim of this study is to compare zoledronic acid treatment to placebo on knee structural change and knee pain over two years. It is hypothesised that zoledronic acid will reduce cartilage loss, knee pain, and bone marrow lesion size.
Vitamin E-bisphosphonate Conjugates: A New Therapeutic Approach Targeting Pathological Bone Loss Associated With Osteoporosis
Funder
National Health and Medical Research Council
Funding Amount
$471,984.00
Summary
Approximately 2 million Australians have osteoporosis, a disease which increases the risk of fracture and whose monetary and social costs are large and growing. The objective of this proposal is to exploit the osteotropic properties of novel compounds of vitamin E (VE) derivatives (BPVE) conjugated to bisphosphonates (BP), which will have anti-oxidant, anti-osteolytic and bone anabolic properties, and will be taken up selectively in the skeleton for the treatment of osteoporosis.
A Randomised Controlled Trial To Evaluate The Effectiveness Of Zoledronate Therapy In Osteonecrosis Of The Hip.
Funder
National Health and Medical Research Council
Funding Amount
$535,441.00
Summary
Osteonecrosis of the hip is an important cause of musculoskeletal disability and finding therapeuticsolutions has proven to be challenging. A wide range of surgical treatments with variable success rates ahve been proposed for the treatment. Non-surgical treatment options are limited and usually result in a poor prognosis. This novel clinical trial research will study the protective value of a bisphosphonate in patients with osteonecrosis of the hip and evaluate the cost-effectiveness.
Bisphosphonate Treatment Of Childhood Femoral Head Avascular Necrosis Due To Perthes Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,368,242.00
Summary
Perthes disease (PD) occurs following loss of blood supply to the hip (femoral head). It is a severe childhood disorder with over 250 new cases per year in Australia. PD results in flattening of the normally round femoral head and painful arthritis. The hip becomes flat because the bone is eaten by cells called osteoclasts. We will test if a medicine aimed at stopping these osteoclasts can prevent hip flattening. This should decrease the risk of arthritis and the need for hip replacement.